Neurology News and Research

Latest Neurology News and Research

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck Inc. today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

29 Jan 2011

Apple Valley Medical Clinic inaugurates new Sleep Center to provide quality care

The Apple Valley Medical Clinic has opened a new Sleep Center, located at 15100 Galaxie Avenue in Apple Valley. The center, under the medical direction of Scott Benson, M.D., a family medicine physician with the Apple Valley Medical Clinic, offers preventive care, diagnosis and treatment of sleep disorders.

28 Jan 2011

Protein Erk necessary for nerve fibers to be wrapped with myelin

Researchers at the University of North Carolina at Chapel Hill have pinpointed a crucial function for a key player in the development of the nervous system. They found that this player - a protein called Erk - is necessary for nerve fibers to be wrapped with an insulating substance called myelin, which allows messages to be sent from the brain to the peripheral limbs and back again.

28 Jan 2011

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

In the early years of the AIDS epidemic, being infected with the virus that causes the disease was considered a virtual death sentence. But with the development of antiretroviral therapy, many with HIV are now living much longer. In fact, it is estimated that by 2015, about half of all HIV-positive individuals will be older than 50.

28 Jan 2011

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

28 Jan 2011

Showman surgeon in an ethical tangle

Dr. Charlie Teo had stirred the hornet’s nest of ethical issues by offering to allow a person to spend a day in his company, including the possibility of watching his intricate excision of brain tumors, as a prize in a charity auction held at the Concord Function Centre to raise funds for childhood cancer research. The prize fetched about $1,500.

27 Jan 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.

25 Jan 2011

Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint

Based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, Eisai Inc. announced today that the company will not submit marketing authorization applications to regulatory authorities in the United States, the European Union and Japan by the end of the fiscal year (March 31, 2011), as previously planned.

25 Jan 2011

Researchers discover new treatment for difficult-to-control high blood pressure

Researchers were surprised to discover what may be a potential new treatment for difficult-to-control high blood pressure, according to a case report published in the January 25, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

25 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

Scientists ignore relevant drug clinical trials when conducting new research on same topic

The vast majority of already published and relevant clinical trials of a given drug, device or procedure are routinely ignored by scientists conducting new research on the same topic, a new Johns Hopkins study suggests.

24 Jan 2011

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Intellipharmaceutics International Inc. today announced that it has received purchase agreement commitments from institutional investors to provide the Company with approximately US$12,000,000 in gross proceeds through the sale of its common stock and warrants.

21 Jan 2011

GSK, Valeant receive European CHMP positive opinion for Trobalt

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Trobalt™ (retigabine) as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

21 Jan 2011

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.

21 Jan 2011

Repligen enters exclusive license agreement with UCI for use of HDAC3 inhibitors for memory disorders

Repligen Corporation announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.

21 Jan 2011

Cognition Therapeutics closes $2.5 million Series A1 financing

Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.

20 Jan 2011

HIV-infected patients three times more likely to suffer strokes

While the overall hospitalization rate for stroke has declined in recent years, the numbers have jumped dramatically for patients infected with human immunodeficiency virus (HIV), suggesting they may be up to three times more likely to suffer a stroke than people uninfected by the virus that causes AIDS.

20 Jan 2011

Brains of migraine sufferers show higher proportion of lesions of brain microvessels

Recent work, in particular the CAMERA study, has used MRI to study the brains of migraine sufferers and has shown that a higher proportion of these patients exhibit lesions of the brain microvessels than the rest of the population.

20 Jan 2011

New research: HIV individuals are more likely to have stroke

New research suggests that people infected with human immunodeficiency virus may be up to three times more likely to have a stroke compared to those not affected with HIV. The study is published in the January 19, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

20 Jan 2011